114 related articles for article (PubMed ID: 22223337)
1. Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.
Ueno Y; Matsuda H; Mizutani H; Iwamoto T; Okuda M
Biol Pharm Bull; 2012; 35(1):54-8. PubMed ID: 22223337
[TBL] [Abstract][Full Text] [Related]
2. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.
Itoh T; Itagaki S; Sumi Y; Hirano T; Takemoto I; Iseki K
Cancer Chemother Pharmacol; 2005 May; 55(5):420-4. PubMed ID: 15565324
[TBL] [Abstract][Full Text] [Related]
3. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic study of cancer chemotherapy].
Itoh T
Yakugaku Zasshi; 2006 Sep; 126(9):723-35. PubMed ID: 16946586
[TBL] [Abstract][Full Text] [Related]
5. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Bouscarel B; Matsuzaki Y; Ceryak S; Kudoh S; Fromm H
Int J Cancer; 1999 Nov; 83(4):491-6. PubMed ID: 10508485
[TBL] [Abstract][Full Text] [Related]
6. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
7. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
8. Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Ceryak S; Matsuzaki Y; Kudoh S; Bouscarel B
Biochim Biophys Acta; 2001 Feb; 1525(1-2):125-9. PubMed ID: 11342261
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
10. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
Tallman MN; Ritter JK; Smith PC
Drug Metab Dispos; 2005 Jul; 33(7):977-83. PubMed ID: 15833930
[TBL] [Abstract][Full Text] [Related]
11. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
12. Common mechanisms of monoacylglycerol and fatty acid uptake by human intestinal Caco-2 cells.
Ho SY; Storch J
Am J Physiol Cell Physiol; 2001 Oct; 281(4):C1106-17. PubMed ID: 11546646
[TBL] [Abstract][Full Text] [Related]
13. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
[TBL] [Abstract][Full Text] [Related]
14. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
15. Uptake of perfluorooctanoic acid by Caco-2 cells: Involvement of organic anion transporting polypeptides.
Kimura O; Fujii Y; Haraguchi K; Kato Y; Ohta C; Koga N; Endo T
Toxicol Lett; 2017 Aug; 277():18-23. PubMed ID: 28552774
[TBL] [Abstract][Full Text] [Related]
16. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).
Gupta E; Luo F; Lallo A; Ramanathan S; Vyas V; Rubin E; Sinko P
Anticancer Res; 2000; 20(2A):1013-6. PubMed ID: 10810389
[TBL] [Abstract][Full Text] [Related]
17. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
18. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
19. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
